BNTX (biontech.de) Market Value to Book Value Ratio

Official company branding of BioNTech Inc. (BNTX)

BioNTech SE (BNTX) is implementing neural networks for molecular modeling and automating production. The asset is currently undergoing a deep update phase following the decline in pandemic-driven demand. The multiple of market capitalization to balance helps assess the fundamental strength of the business, with the latest value recorded as 1.06. Redirecting funds into the mRNA-based oncology pipeline effectively reduces patent dependency.

BNTX BioNTech Pharma: Market Value to Book Value in the range 07/04/2022 - 10/27/2026
Original product of BioNTech Group

This indicator compares the market value of BioNTech SE (BNTX) to its net assets, measuring the premium investors are willing to pay for future growth potential. Analyzing the market-to-book ratio on GURU.Markets reveals that a significant liquidity reserve from previous vaccine sales stabilizes the valuation, offsetting the risk of a sharp price drop should revenue decelerate.

Main competitors

Market Cap to Net Assets Ratio argenx SE|ABVX (ABIVAX) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio ADMA Biologics, Inc. ADMA|Market Capitalization to Net Assets Protagonist Therapeutics, Inc.|Immunovant Corp (IMVT) - Market Capitalization to Book Value Ratio|Market Value to Book Value Kiniksa Corp (KNSA)|Market Capitalization to Book Value Ratio GRFS (Grifols, S.A.)|adaptivebiotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Celldex Therapeutics, Inc. (CLDX)|AUPH: Market Value to Book Value|BCRX (BioCryst Pharmaceuticals Inc) - Market Value to Book Value Ratio|Vera Corp (VERA) - Market Cap to Net Assets Ratio|DNTH (Dianthus Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pharvaris.com (PHVS)|AbCellera Bio (ABCL) - Market Cap to Net Assets Ratio|Market Value to Book Value Tourmaline Bio Inc (TRML)|Market Capitalization to Book Value Ratio PGEN|Pharming Corp - Market Capitalization to Book Value|NKTR: Market Value to Book Value Ratio|UPB: Market Cap to Net Assets Ratio|ZBIO (Zenas Biopharma) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Immunome Inc|GOSS (Gossamer Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio KALV|Market Value to Book Value Ratio Septerna Inc SEPN|Capitalization to Book Value Ratio pieris.com (PVLA)|SVRA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rigel Pharma RIGL|ANAB - Market Capitalization to Book Value Ratio|ATXS - Market Value to Book Value Ratio|enGene Holdings Inc. - Market Capitalization to Book Value Ratio|RAPT (rapt.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio JBIO (Aerovate Therapeutics, Inc.)|Market-to-Book Ratio ACRS|Market Value to Book Value Ratio Kyverna KYTX|Capitalization to Book Value Ratio Tiziana Life Sciences, Ltd. TLSA|Market Cap to Net Assets Ratio Cabaletta Bio, Inc. (CABA)|Market Cap to Book Value Multiple ventyxbio.com VTYX|THTX (Theratechnologies) - Market Capitalization to Book Value Ratio|AVTX - Market-to-Book Ratio|ELDN (Eledon) - Market Capitalization to Book Value Ratio|Agenus, Inc (AGEN) - Market Cap to Net Assets Ratio|CLYM - Market Capitalization to Book Value Ratio|Market Value to Book Value zurabio.com (ZURA)|aTyr Pharma (ATYR) - Market Cap to Net Assets Ratio|Market Value to Book Value ADAG (adagene.com)|Market Value to Book Value Ratio IMA|Market Capitalization to Book Value Shattuck Labs Inc STTK|EQ (Equillium Bio) - Market Capitalization to Book Value Ratio|CNTB - Market-to-Book Ratio|immunic-therapeutics.com (IMUX) - Market Capitalization to Book Value Ratio|ATRA (Atara Bio) - Market Value to Book Value Ratio|Market Value to Book Value Ratio InflaRx NV (IFRX)|Capitalization to Book Value Ratio X4 Pharmaceuticals, Inc (XFOR)|Market Cap to Net Assets Ratio Adicet Bio|Market Cap to Book Value Multiple celularity.com CELU|INMB - Market Cap to Net Assets Ratio|Barinthus Biotherapeutics PLC - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Kezar Life Sciences, Inc|SABS - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio Akari Therapeutics AKTX|Enlivex Therapeutics Ltd. (ENLV) - Market Value to Book Value|QTTB (Q32 Bio Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio GOVX|Edesa (EDSA) - Market Value to Book Value Ratio|Market Value to Book Value IBIO (iBio Corporation)|Carisma Therapeutics Inc. - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio xtlbio.com XTLB|Bolt Bio - Market Capitalization to Book Value Ratio|HCW Biologics Inc. (HCWB) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio aptevotherapeutics.com APVO|aimimmuno.com (AIM) - Market Value to Book Value|ADTX: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value GRI|Market Value to Book Value Ratio XRTX (XORTX Therapeutics)|Market Cap to Net Assets Ratio HIND (Vyome Holdings Inc.)|Revelation Bio - Market Value to Book Value Ratio|INDP - Market Cap to Net Assets Ratio|Scinai Immunotherapeutics - Market Cap to Net Assets Ratio|CALI: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio affimed.com|Allakos (ALLK) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio HOOK (HOOKIPA Pharma, Inc.)|Market-to-Book Ratio IGM Bio|Market Capitalization to Book Value Ratio iTeos Therapeutics (ITOS)|Market Value to Book Value Ratio oceanbiomedical.com (OCEA)|Market Capitalization to Book Value Ratio TCBP|Third Harmonic Bio Inc. - Market Capitalization to Book Value